|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LINC00493 |
Gene summary for LINC00493 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LINC00493 | Gene ID | 388789 |
| Gene name | small integral membrane protein 26 | |
| Gene Alias | LINC00493 | |
| Cytomap | 20p11.23 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 388789 | LINC00493 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 3.80e-25 | 5.01e-01 | 0.294 |
| 388789 | LINC00493 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 3.42e-04 | 6.78e-01 | 0.3487 |
| 388789 | LINC00493 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.71e-10 | 3.60e-01 | 0.281 |
| 388789 | LINC00493 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 4.93e-21 | 4.13e-01 | 0.3859 |
| 388789 | LINC00493 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 2.22e-05 | 2.68e-01 | 0.2585 |
| 388789 | LINC00493 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 3.80e-25 | 4.50e-01 | 0.3005 |
| 388789 | LINC00493 | LZE4T | Human | Esophagus | ESCC | 1.22e-07 | -4.58e-01 | 0.0811 |
| 388789 | LINC00493 | LZE7T | Human | Esophagus | ESCC | 2.77e-03 | -4.58e-01 | 0.0667 |
| 388789 | LINC00493 | LZE8T | Human | Esophagus | ESCC | 8.84e-07 | -4.58e-01 | 0.067 |
| 388789 | LINC00493 | LZE20T | Human | Esophagus | ESCC | 6.33e-07 | -4.58e-01 | 0.0662 |
| 388789 | LINC00493 | LZE22D1 | Human | Esophagus | HGIN | 4.08e-03 | -4.58e-01 | 0.0595 |
| 388789 | LINC00493 | LZE24T | Human | Esophagus | ESCC | 2.22e-11 | -4.58e-01 | 0.0596 |
| 388789 | LINC00493 | LZE6T | Human | Esophagus | ESCC | 4.21e-04 | -4.58e-01 | 0.0845 |
| 388789 | LINC00493 | P1T-E | Human | Esophagus | ESCC | 4.25e-14 | 1.22e+00 | 0.0875 |
| 388789 | LINC00493 | P2T-E | Human | Esophagus | ESCC | 6.86e-39 | 8.90e-01 | 0.1177 |
| 388789 | LINC00493 | P4T-E | Human | Esophagus | ESCC | 1.31e-40 | 1.47e+00 | 0.1323 |
| 388789 | LINC00493 | P5T-E | Human | Esophagus | ESCC | 6.88e-31 | 7.46e-01 | 0.1327 |
| 388789 | LINC00493 | P8T-E | Human | Esophagus | ESCC | 2.43e-42 | 1.06e+00 | 0.0889 |
| 388789 | LINC00493 | P9T-E | Human | Esophagus | ESCC | 4.88e-39 | 1.43e+00 | 0.1131 |
| 388789 | LINC00493 | P10T-E | Human | Esophagus | ESCC | 1.61e-76 | 1.47e+00 | 0.116 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| LINC00493 | SNV | Missense_Mutation | novel | c.7N>G | p.Arg3Gly | p.R3G | protein_coding | tolerated(0.35) | benign(0.012) | TCGA-A2-A3XT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | PR | |
| LINC00493 | SNV | Missense_Mutation | novel | c.20C>T | p.Thr7Met | p.T7M | protein_coding | tolerated(0.21) | possibly_damaging(0.54) | TCGA-LL-A73Z-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| LINC00493 | SNV | Missense_Mutation | novel | c.237N>T | p.Lys79Asn | p.K79N | protein_coding | deleterious(0.01) | possibly_damaging(0.857) | TCGA-BK-A6W3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |